Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 11/2007

01-11-2007

The Surgeon’s Role in Cancer Prevention. The Model in Colorectal Carcinoma

Authors: David Z. J. Chu, MD, Glen Gibson, MD, Donald David, MD, Yun Yen, MD

Published in: Annals of Surgical Oncology | Issue 11/2007

Login to get access

Abstract

Cancer Prevention is an emerging field, capturing the old traditional concept of anticipating the development of a major disease and preventing its full impact by early detection, treatment, or aborting the tumorigenic process by a “molecular vaccine” and alleviating the full impact of the disease. Surgeons are important clinician scientists who can carry this discipline forward and develop its full potential in the clinics and in the community. Advances in molecular biology, genetics, and other technologies have permitted seminal understanding of the carcinogenic pathways and identification of targets and intermediate end points in neoplasia. In this review, we will see that we have the means of preventing significant numbers of colorectal carcinomas (CRC).
Literature
1.
O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, et al. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 2002; 8:314–46PubMed
2.
Umar A, Viner JL, Richmond E, Anderson WF, Hawk ET. Chemoprevention of colorectal carcinogenesis. Int J Clin Oncol 2002; 7:2–26PubMed
3.
Sporn MB, Suh N. Chemoprevention: an essential approach to controlling cancer. Nature Rev 2002; 2:537–43
4.
Wolff J. The Science of Cancerous Disease from Earliest Times to the Present. Watson Publishing International, 1989:3. Republished from, Vol I, Die Lehre von der Krebskrankheitvon den altenten Zeiten bis zur Gegenwart, 1907
5.
Olson JS. The History of Cancer—An Annotated Bibliography. New York: Greenwood Press, 1989:41
6.
Berlin NI. The conquest of cancer. Perspect Biol Med 1979; Summer 22(4):500–18
7.
Gilman A, Philips FS. The biological actions and therapeutic application of β-chloroethyl amines and sulfides. Science 1946; 103:409PubMed
8.
Schwartz LM, Woloshin S, Fowler FJ, Welch HG. Enthusiasm for cancer screening in the U.S. JAMA 2004; 291:71–8PubMed
9.
Vainio H, Miller AB. Primary and secondary prevention in colorectal cancer. Acta Oncol 2003; 42:809–15PubMed
10.
Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, Rothenberger DA, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002; 95:1618–28PubMed
11.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M. Cancer Statistics 2007. CA Cancer J Clin 2007; 57:43–66PubMed
12.
13.
Yiu HY, Whittemore AS, Shibata A. Increasing colorectal cancer incidence rates in Japan. Int J Cancer 2004; 109:777–81PubMed
14.
Flood DM, Weiss NS, Cook LS, Emerson JC, Schwartz SM, Potter JD. Colorectal cancer incidence in Asian migrants to the United States and their descendants. Cancer Causes Control. 2000; 11:403–11PubMed
15.
Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutrition J 2004; 3(19):1–37
16.
Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75:1027–38PubMed
17.
Ueda E, Watanabe T, Umetami N, Ishigami H, Sasaki S, Nagawa H. Microsatellite instability of cancers and concomitant adenomas in synchronous multiple colorectal cancer patients. J Exp Clin Cancer Res 2002; 21:149–54PubMed
18.
Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Seminars Cancer Biol 2004; 14:473–86
19.
Goel A, Arnold CN, Niedzwiecki D, Chang DK, Riciardiello L, et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003; 63:1608–14PubMed
20.
Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst 1999; 91:916–32PubMed
21.
Giovannucci E, Martinez ME. Tobacco, colorectal cancer, and adenomas: a review of the evidence. J Natl Cancer Inst 1996; 88:1717–30PubMed
22.
Terry P, Ekbom A, Lichtenstein P, Feychting M, Wolk A. Long-term tobacco smoking and colorectal cancer in a prospective cohort study. Int J Cancer 2001; 91:585–7PubMed
23.
Colangelo LA, Gapstur SM, Gann PH, Dyer AR. Cigarette smoking and colorectal carcinoma mortality in a cohort with long-term follow-up. Cancer 2004; 100:288–93PubMed
24.
Lieberman DA, Prindiville S, Weiss DG, Willet W. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals, JAMA 2003; 290:2959–67PubMed
25.
McCullough ML, Giovannucci EL. Diet and cancer prevention. Oncogene 2004; 23:6349–64PubMed
26.
Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. Eur J Cancer 2001; 37:948–65PubMed
27.
Boyle P, Leon ME. Epidemiology of colorectal cancer. Brit Med Bull 2002; 64:1–25PubMed
28.
MacLennan R, Macrae R, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. J Natl Cancer Inst 1995; 87:1760–66PubMed
29.
Alberts DS, Martinez ME, Roe Dj, et al. Phoenix Colon Cancer Prevention Physicians’ Network. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1156–62PubMed
30.
Schatzkin A, Lanza E, Corle D, et al. Polyp Prevention Trial Study group. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. N Engl J Med 2000; 342:1149–55PubMed
31.
Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging and cancer prevention: Mechanisms of action and applicability to humans. Ann Rev Med 2003; 54:131–52PubMed
32.
Bingham SA, Day NE, Luben R, Rerrari P, Slimani N, et al. Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. Lancet 2003; 361:1496–1501PubMed
33.
Lipkin M. Preclinical and early human studies of calcium and colon cancer prevention. Ann NY Acad Sci 1999; 889:120–7PubMed
34.
Friedenreich CM, Orentein MR. Physical activity and cancer prevention: Etiologic evidence and biological mechanisms. J Nutr 2002; 132:3456S–64SPubMed
35.
Cho KR, Vogelstein B. Genetic alterations in the adenoma-carcinoma sequence. Cancer 1992; 70(6 Suppl):1727–31PubMed
36.
Bertario L, Russo A, Sala P, Varesco L, Giarola M, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21:1698–707PubMed
37.
Su LK, Kohlmann W, Ward PA, Lynch PM. Different familial adenomatous polyposis phenotypes resulting from deletions of the entire APC exon 15. Hum Genet 2002; 111:88–95PubMed
38.
Lovig T, Melig GI, Diep CB, Thorstensen L, Norheim AS, et al. APC and CTNNB1 mutations in a large series of sporadic colorectal carcinomas stratified by the microsatellite instability status. Scand J Gastroenterol 2002; 37(10):1184–93PubMed
39.
Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 2000; 9:1967–79
40.
Lynch HT, Shaw MW, Magnuson CW, Larsen Al, Krush AJ. Hereditary factors in cancer. Study of two large Midwestern kindreds. Arch Intern Med 1966; 117:206–212PubMed
41.
Peel DJ, Ziogas A, Fox EA, Gildner M, Laham E, Kolodner RD, Anton-Culver H. Characterization of hereditary nonpolyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2000; 92:1517–22PubMed
42.
Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10:789–99PubMed
43.
Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003; 21:1174–9PubMed
44.
Boland R. Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol 2007; 25:754–6PubMed
45.
Vasen HFA, Watson P, Mecklin JP, Lynch HT, et al. New clinical criteria for HNPCC (Lynch Syndrome) proposed by the international Collaborative Group on HNPCC. Gastroenterol 1999; 116:1453–56
46.
Vasen HFA, Mecklin JP, Meera KP, et al. The international collaborative Group on hereditary non-polyposis colorectal cancer (ICG-HNPCC) Dis Colon Rectum 1991; 34:424–5PubMed
47.
Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterol 2001; 121:198–213
48.
Chung DC, Turstgi AK. The hereditary nonpolyposis colorectal cancer syndrome: Genetics and clinical implications. Ann Intern Med 2003; 138:560–70PubMed
49.
Brink M, Goeij AFPM, Weijenberg MP, Roemen GMJM, Lentjes MHFM, et al. K-ras oncogene mutations in sporadic colorectal cancer in the Netherlands Cohort Study. Carcinogenesis 2003; 24:703–10PubMed
50.
Villa E, Dugani A, Rebecchi AM, Vignoli A, Grottola A, Buttafoco P, et al. Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology 1996; 110:1346–53PubMed
51.
Sharma S, Kemeny N, Kelsen DP, Ilson D, O’Reilly E, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol 2002; 13(7):1067–71PubMed
52.
Salahshor S, Kressner U, Pahlman L, Glimelius B, Lindmark G, Lindblom A. Colorectal cancer with and without microsatellite instability involves different genes. Genes Chromosomes Cancer 1999; 26:247–52PubMed
53.
Kressner U, Inganas M, Byding S, Blikstad I, Pahlman L, Glimelius B, et al. Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol 1999; 17:593–9PubMed
54.
Roth S, Sistonen P, Salovaara R, Hemminki A, Loukola A, et al. SMAD genes in juvenile polyposis. Genes Chromosomes Cancer 1999; 26:54–61PubMed
55.
Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998; 18:38–43PubMed
56.
De Leng WWJ, Westerman AM, Weterman MAJ, de Rooij FWM, van Dekken H, de Goeij AFPM, et al. Cyclooxygenase 2 expression and molecular alterations in Peutz-Jeghers hamartomas and carcinomas. Clin Cancer Res 2003; 9:3065–72PubMed
57.
Furukawa T, Konishi F, Masubuchi S, Shitoh K, Nagai H, Tukamoto T. Densely methylated MLH1 promoter correlates with decreased mRNA expression in sporadic colorectal cancers. Genes Chromosomes Cancer 2002; 35:1–10PubMed
58.
Jubb AM, Bell SM, Quirke P. Methylation and colorectal cancer. J Pathol 2001; 195:11–34
59.
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999; 96:8681–86PubMed
60.
Chan AO, Broaddus RR, Houlihan PS, Issa JJ, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol 2002; 160:1823–30PubMed
61.
Jass JR, Whitehall VLJ, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterol 2002; 123:862–76
62.
Yuen ST, Chan TL, Ho JW, Chan AS, Chung LP, et al. Germline, somatic and epigenetic events underlying mismatch repair deficiency in colorectal and HNPCC-related cancers. Oncogene 2002; 21:7585–92PubMed
63.
Parsons R, Myeroff LL, Liu B, Wilson J, Markowitz SD, Kinsler KW, et al. Microsatellite instability and mutations of the transforming growth factor β type II receptor gene in colorectal cancer. Cancer Res 1995; 55: 5548–50
64.
Vincent F, Hagiwara K, Ke Y, Stoner GD, Demetrick DJ, Benett WP. Mutations analysis of the transforming growth factor B type II receptor in sporadic human cancers of the pancreas, liver and breast. Biochem Biophys Res Commun 1996; 223:561–4PubMed
65.
Boland CR, Thibodeau SN, Hamilton SR, et al. A NCI workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58:5248–57PubMed
66.
Young J, Simms LA, Biden KG, Wynter C, Whitehall V, et al. Features of colorectal cancers with high-level MSI occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159:2107–16PubMed
67.
Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Eng J Med 2003; 349:247–57
68.
Cappel WN, Meulenbeld HJ, Kleibeuker JH, Nagengast FM, Menko FH, et al. Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer. Int J Cancer 2004; 109:468–71
69.
Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23:11–27PubMed
70.
Chu DZJ, Giacco G, Martin RG, Guinee VF. The significance of synchronous carcinoma and polyps in the colon and rectum. Cancer 1986; 57:445–50PubMed
71.
Mattar M, Frankel P, David D, Clark KO, Chu DZJ, Jian C, Yen Y. Clinicopathologic significance of synchronous and metachronous adenomas in colorectal cancer. Clin Colorectal Cancer. 2005; 5:274–8PubMed
72.
Frederiksen CM, Knudsen S, Laurberg S, Orntoft TF. Classification of Duke’s B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol 2003; 129:263–71PubMed
73.
Huerta S, Harris DM, Jazirchi A, Bonavida B, Elashoff D, Livingston E, Herber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol 2003; 22:663–70PubMed
74.
Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Therap 2002; 1:1035–42
75.
Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002, 21:4120–28PubMed
76.
Hendriks Y, Franken P, Kierssen JW, De Leeuw W, Wijnen J, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol 2003; 12:50–6
77.
Mariadason JM, Arango D, Corner GA, Aranes MJ, Hotchkiss KA, et al. A gene expression profile that defines colon cell maturation in vitro. Cancer Res 2002; 62:4791–4804PubMed
78.
Iizaka M, Furukawa Y, Tsunoda T, Akashi H, Ogawa M, Nakamura Y. Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun 2002; 292:498–512PubMed
79.
Lechner S, Muller-Ladner U, Renke B, Scholmerich J, Ruschoff J, Kullmann F. Gene expression pattern of laser microdissected colonic crypts or adenomas with low grade dysplasia. Gut 2003; 52:1148–53PubMed
80.
Williams NS, Gaynor RB, Scoggin S, Verma U, Gokasian T. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9:931–46PubMed
81.
Zou TT, Selary FM, Xu Y, Shustova V, Yin J, Mori Y, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002; 21:4855–62PubMed
82.
Tureci O, Ding J, Hilton H, Bian H, Ohkawa, Braxenthaler M, et al. Computational dissection of tissue contamination for identification of colon cancer-specific expression profiles. FASEB J 2003; 17:376–85
83.
Calvert PM, Frucht H. The genetics of colorectal cancer. Ann Intern Med 2002; 137:603–12PubMed
84.
De Jong MM, Nolte IM, Meerman FJ, van der Graaf WTA, de Vries EGE, et al. Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 2002; 11:1332–52PubMed
85.
Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer 2006; 8:1790–7
86.
Martinez ME, O’Brien TG, Fultz KE, Babbar N, Yerushalmi H, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. PNAS 2003; 100:7859–64PubMed
87.
Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Eng J Med 2003; 348:791–9
88.
Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677 C → T polymorphism affect cancer risk: intake recommendations. J Nutr 2003; 133:3748S–53SPubMed
89.
90.
Kelloff GJ, Sigman CC, Greenwald P. Cancer chemoprevention: progress and promise. Eur J Cancer 1999; 35:1755–62PubMed
91.
Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004; 54:150–80PubMed
92.
Sandler RS, Baron JA, Tosteson TD, Mandel JS, Haile RW. Rectal mucosal proliferation and risk of colorectal adenomas: results from a randomized controlled trial. Cancer Epidemiol Biomarkers Prev 2000; 9:653–6PubMed
93.
Kim KP, Whitehead C, Piazza G, Wargovich MJ. Combinatorial chemoprevention: efficacy of lovostatin and exisulind on the formation and progression of aberrant crypt foci. Anticancer Res 2004; 24:1805–11PubMed
94.
Greenberg ER, Baron JA. Aspirin and other nonsteroidal anti-inflammatory drugs as cancer-preventive agents. In Stewart BW McGregor D (ed) Principles of Chemoprevention. IARC Scientific Publication No. 139, Lyon: International Agency for Research on Cancer, 1996
95.
Shaheen NJ, Straus WL, Sandler RS. Chemoprevention of gastrointestinal malignancies with nonsteroidal anti-inflammatory drugs. Cancer 2002; 94:950–63PubMed
96.
Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94:252–66PubMed
97.
Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24:83–7PubMed
98.
Church RD, Fleshman JW, McLeod HL. Cyclooxygenase 2 inhibition in colorectal cancer therapy. Brit J Surg 2003; 90:1055–67PubMed
99.
Arber N, Eagle CJ, Spivak J, Racz I, Diter J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885–95PubMed
100.
Bertagnoli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355:873–84
101.
Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804PubMed
102.
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med, 2003; 348:891–9
103.
Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med, 2003; 348:883–90
104.
Chan AT, Giovanucci EL, Shernhammer S, Colditz GA, Hunter FG, Willett, Fuchs: A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004; 140:157–66
105.
Martinez ME, Willett WC. Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prevention, 1998; 7:163–8
106.
Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999; 340:101–7PubMed
107.
Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomized intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000; 356:1300–6PubMed
108.
Chu D, Alberts DS, Hussey M, Meyskens F, Fenoglio-Preiser CM, et al. Supplemental calcium and colorectal adenomas in individuals with resected colorectal carcinoma: results from a SWOG feasibility study. Frontiers in Cancer Prevention Research 2006; page 174, abstract B143
109.
Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354:687–696
110.
Meyskens Fl, Gerner EW. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 1999; 5:945–51PubMed
111.
Pegg AE, Shantz LM, Coleman CS. Ornithine decarboxylase as a target for chemoprevention. J Cell Biochem 1995; 22 Suppl:132–38
112.
Lawson KR, Ignatenko NA, Piazza GA, Cui H, Gerner EW. Influence of k-ras activation on survival responses of caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarker Prev 2000; 9:1155–62
113.
Jacoby RF, Cole CE, Tutsch K, Newton NA, Kelloff G, Hawk ET, Lubet RA. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 2000; 60:1864–70PubMed
114.
Babbar N, Gerner EW. Polyamines as modifiers of genetic risk factors in human intestinal cancers. Biochem Soc Trans 2003; 31:388–92PubMed
115.
Lu SC, Alvarez L, Huang ZZ, Chen L, An W, Corrales FJ, Avila MA, et al. Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. PNAS 2001: 98:5560–65PubMed
116.
Baron JA, Cole BF, Mott L, Haile R, Grau M, et al. Neoplastic and Antineoplastic effects of β-Carotene on colorectal adenoma recurrence: Results of a randomized trial. J Natl Cancer Inst 2003; 95:717–722PubMedCrossRef
117.
Albanes D, Malila N, Taylor PR, et al. Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland). Cancer Causes Control 2000:11:197–205PubMed
118.
Whanger PD. Selenium and its relationship to cancer: an update dagger. Br J Nutr 2004; 91:11–28PubMed
119.
Seifried HE, McDonald SS, Anderson DE, Greenwald P, Milner JA. The antioxidant conundrum in cancer. Cancer Res 2003; 63:4295–8PubMed
120.
Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF, Slate EH, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the Nutritional Prevention of Cancer Trial. Cancer Epidemiol Biomarkers Prev 2002; 11:630–9PubMed
121.
Wingo PA, Ries LAG, Rosenberg HM, Miller DS, Edwards BK. Cancer incidence and mortality 1973–1995. Cancer 1998; 82:1197–207PubMed
122.
Potter JD. Hormones and colon cancer. J Natl Cancer Inst 1995; 87:1039–40PubMed
123.
MacLennan SC, MacLennan AH, Ryan P. Colorectal cancer and estrogen replacement therapy: a meta-analysis of epidemiological studies. Med J Aust 1995; 162:491–3PubMed
124.
Chlebowski RT, Wactowski-Wende J, Ritenbaugh C, Hubbell FA, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004; 350:991–1004PubMed
125.
Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res 2001; 61:126–130PubMed
126.
Trialist; Early Breast Cancer Trialists’ Collaborative Group: Tamoxifen for early breast Cancer. Cochrane Database Syst Rev 2001; 1:CD000486
127.
Kopelovich L, Crowell JA, Fay JR. The epigenome as a target for cancer chemoprevention. J Natl Cancer Inst 2003; 95:1747–57PubMed
128.
129.
Jothy S, Slesak B, Harlozinska A, Lapinska J, Adamiak J, Baczynski J. Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol 1996; 58–64
130.
Braakhuis BJM, Tabor MP, Dummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter’s concept of field cancerization: Evidence and clinical implications. Cancer Res 2003; 63:1727–30PubMed
131.
Guo Z, Yamaguchi K, Snachez-Cepedes M, Westra WH, Koch Wm, Sidransky D. Allelic losses in Ora Test-directed biopsies of patients with prior upper aerodigestive tract malignancy. Clin Cancer Res 2001; 7:1963–68PubMed
132.
Loeve F, Ballegooijen M, Boer R, Kuipers EJ, Habbema JDF. Colorectal cancer risk in adenoma patients: A nation-wide study. Int J Cancer 2004; 111:147–51PubMed
133.
Itzkowitz SH, Yio X. Inflammation and cancer: IV. Colorectal cancer in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G7–17PubMed
134.
Hemminski K, Li X, Czene K. Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 2004; 108:109–14
135.
van Stolk RU. Familial and inherited colorectal cancer: endoscopic screening and surveillance. Gastrointest Endosc Clin N Am 2002; 12:111–33PubMed
136.
Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterol 2003; 124:1574–94
137.
Lynch HT, de la Chapelle A. Genomic Medicine: Hereditary Colorectal Cancer. N Eng J Med 2003; 348:919–32
138.
Crabtree MD, Lomlinson IP, Hodgson SV, Neale K, Phillips RK, Houlston RS. Explaining variation in familial adenomatous polyposis: relationship between genotype and phenotype and evidence for modifier genes. Gut 2002; 51:306–8
139.
Giardello FM, Bresinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterol 2001; 121:198–213CrossRef
140.
Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch Syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96:261–8PubMedCrossRef
141.
Sayed MG, Ahmed AF, Ringold JR, Anderson ME, Bair JL, Mitros FA, Lynch HT, et al. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002; 9:901–6PubMed
142.
Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A, et al. Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Brit J Cancer 2003; 89:308–13PubMed
143.
Driver JA, Gaziano JM, Gelber RP, Lee IM, Buring JE, Kurth T. Development of a risk score for colorectal cancer in men. Am J Med 2007; 120:257–263PubMed
144.
Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, et al. Investigation of interaction between N- acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer. Carginogenesis 2003; 24:275–282
145.
Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000; 24:137–42PubMed
146.
Moslein G, Pistorius S, Saeger HD, Schackert HK. Preventive surgery for colon cancer in familial adenomatous polyposis and hereditary nonpolyposis and hereditary nonpolyposis colorectal cancer syndrome. Langenbecks Arch Surg 2003; 388:9–16PubMed
147.
Lynch HT, et al. Is there a role for prophylactic subtotal colectomy among hereditary nonpolyposis colorectal cancer germline mutation carriers? Dis Colon Rectum 1996; 39:109–110PubMed
148.
Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome. JAMA 2006; 296:1507–17PubMed
149.
Lynch HT, Lanspa SJ, Boman Bm, Smyrk T, Watson P, Lynch JF, et al. Hereditary nonpolyposis colorectal cancer—Lynch syndromes I and II. Gastroenterol Clin North Am 1988; 17:679–712PubMed
150.
You YN, Lakhani VT, Wells SA. The role of prophylactic surgery in cancer prevention. World J Surg 2007; 31:450–64PubMed
151.
Rodriguez-Bigas MA, Vasen HF, Pekka-Mecklin J, Myrhoj T, Rozen P, Bertario L, et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 1997; 225:202–7PubMed
152.
Walsh JME, Terdiman JP. Colorectal Cancer Screening. JAMA 2003; 289:1288–96PubMed
153.
Jorgensen OD, Kronborg O, Fenger C. A randomized study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut 2002; 50:29–32PubMed
154.
Pignone M, Rich M, Teutsch SM, Berg AO, Lohr KN. Screening for colorectal cancer in adults at average risk: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 137:132–41PubMed
155.
Levin B, Smith RA, Feldman GE, Colditz GA, Fletcher RH, Nadel M, Rothenberger DA, et al. Promoting early detection tests for colorectal carcinoma and adenomatous polyps: a framework for action: the strategic plan of the National Colorectal Cancer Roundtable. Cancer 2002; 95:1618–28PubMed
156.
Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329:1977–81PubMed
157.
Hoff G, Sauar J, Vatn MH, Larsen S, Langmark K, et al. Polypectomy of adenomas in the prevention of colorectal cancer: 10 years’ follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol 1996; 31:1006–10PubMed
158.
Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348:879–80PubMed
159.
Kushi L, Giovannucci E. Dietary fat, cancer. Am J Med 2002; 113 suppl 9B:63s–70sPubMed
160.
Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002; 360:861–68PubMed
161.
Eyre H, Kahn R, Robertson RM, et al. Preventing cancer, cardiovascular disease, and diabetes. A common agenda for the American Cancer Society, The American Diabetes Association, and the American Heart Association. Stroke 2004; 35:1999–2010PubMed
162.
Byers T, Nestle M, McTierman A, Doyle C, Currie-Williams A, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention. CA Cancer J Clin 2002; 52:92–119PubMed
163.
Colbert LH, Lanza E, Ballard-Barbash R, Slattery ML, Tangrea JA, et al. Adenomatous polyp recurrence and physical activity in the Polyp Prevention Trial (US). Cancer Causes Control 2002; 13:445–53PubMed
164.
Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946–52PubMed
165.
Grau MV, Baron JA, Sandler RS. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003; 95:1765–71PubMed
166.
Cole BF, Baron JA, Sandler RS, Haile Rw, Ahnen DJ, et al. Folic acid for the prevention of colorectal adenomas. JAMA 2007; 297:2351–2359PubMed
167.
Sabichi AL, Demierre MF, Hawk ET, Lerman CE, Lippman SM. Frontiers in cancer prevention research. Cancer Res 2003; 63:5649–55PubMed
Metadata
Title
The Surgeon’s Role in Cancer Prevention. The Model in Colorectal Carcinoma
Authors
David Z. J. Chu, MD
Glen Gibson, MD
Donald David, MD
Yun Yen, MD
Publication date
01-11-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 11/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9485-6

Other articles of this Issue 11/2007

Annals of Surgical Oncology 11/2007 Go to the issue

Editorials

Lumpectomy or Mastectomy: Is Quality of Life the Tie-Breaker?

Breast Oncology

The Effect of Multiple Reexcisions on the Risk of Local Recurrence After Breast Conserving Surgery

Gastrointestinal Oncology

A Phase II Study of Gemcitabine and Capecitabine in Advanced Cholangiocarcinoma and Carcinoma of the Gallbladder: A Single-Institution Prospective Study

Hepatic and Pancreatic Tumors

Hepatitis B Virus Infection Predicts Extrahepatic Metastasis After Hepatic Resection in Patients With Large Hepatocellular Carcinoma

Original Papers

Plasminogen Activator System Localization in 60 Cases of Ductal Carcinoma In Situ

Gastrointestinal Oncology

Short-Term Outcomes After Robotic-Assisted Total Mesorectal Excision for Rectal Cancer